Business
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada\n\n\n\n MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (\"Knight\") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT\n \n ®\n \n has been accepted for review by Health Canada.\n \n\n CREXONT\n \n ®\n \n is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease. The innovative design of CREXONT\n \n ®\n \n allows for rapid onset, while leveraging a mucoadhesive polymer for slow LD release, potentially enabling longer LD absorption in the gut. CREXONT\n \n ®\n \n is expected to compete in a market size of over $50 million in Canada and over $120 million in Brazil. In each of these markets, the controlled release portion of the market was $15 million, during the twelve-month period ended on September 2024, according to IQVIA.\n \n\n In January 2024, Knight announced that it had entered into an agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (\"Amneal\") for the exclusive rights to seek regulatory approval and commercialize CREXONT\n \n ®\n \n in Canada and Latin America. Knight is also working to submit the marketing authorization application in Mexico and Brazil during 2025.\n \n\n \"The submission of CREXONT\n \n ®\n \n in Canada highlights Knight's ongoing commitment to enhancing our central nervous system (CNS) portfolio,\" said Samira Sakhia, President and CEO of Knight. \"With a significant unmet medical need in Parkinson’s disease treatment, CREXONT\n \n ®\n \n will offer a valuable new therapeutic option for the patients.\"\n \n\n\n About CREXONT\n \n\n ®\n \n\n\n CREXONT\n \n ®\n \n is a novel, oral formulation of carbidopa/levodopa (CD/LD) capsule that combines both immediate-release granules and extended-release beads for the treatment of Parkinson’s disease.\n \n\n CREXONT\n \n ®\n \n contains immediate-release (IR) granules and extended-release (ER) coated beads. The IR granules consist of CD and LD, with a disintegrant polymer to allow for rapid dissolution. The ER beads consist of LD, coated with a sustained release polymer ...